ABSTRACT: Autografts have been shown to stimulate osteogenesis, osteoclastogenesis, and angiogenesis, and subsequent rapid graft incorporation. Large structural allografts, however, suffer from limited new bone formation and remodeling, both of which are directly associated with clinical failure due to non-unions, late graft fractures, and infections, making it a priority to improve large structural allograft healing. We have previously shown the osteogenic ability of a polymer-coated allograft that delivers bone morphogenetic protein-2 both in vitro and in vivo through both burst release and sustained release kinetics. In this study, we have demonstrated largely sequential delivery of bone morphogenetic protein-2 and vascular endothelial growth factor from the same coated allograft. Release data showed that loading both growth factors onto a polymeric coating with two different techniques resulted in short-term (95% release within 2 weeks) and long-term (95% release within 5 weeks) delivery kinetics. We have also demonstrated how released VEGF, traditionally associated with angiogenesis, can also provide a stimulus for allograft remodeling via resorption. Bone marrow derived mononuclear cells were co-cultured with VEGF released from the coated allograft and showed a statistically significant (p < 0.05) and dose dependent increase in the number of tartrate-resistant acid phosphatase-positive multinucleated osteoclasts. Functionality of these osteoclasts was assessed quantitatively and qualitatively by evaluating resorption pit area from both osteo-assay plates and harvested bone. Data indicated a statistically significant higher resorption area from the cells exposed to VEGF released from the allografts over controls (p < 0.05). These results indicate that by using different loading protocols temporal control can be achieved when delivering multiple growth factors from a polymer-coated allograft. Further, released VEGF can also stimulate osteoclastogenesis that may enhance allograft incorporation, and thus mitigate long-term clinical complications. ß
Bone grafting procedures are on the rise in the US, with an estimated two million grafting procedures performed annually. 1 Autografts, donor tissues harvested from the patient's own body, are considered the gold standard for their optimal biocompatibility, osteoconductivity, ideal biomechanical properties, biological components, and subsequent osteoinductivity, leading to an 80-90% success rate clinically. 2, 3 Autografts are typically harvested from the iliac crest for its porous trabecular bone, relative ease of access, and the high marrow content taken with the bone because of its abundant cells, blood, and associated proteins. Autograft incorporation follows a similar sequence of events as typical fracture repair including inflammation, repair, and remodeling. 4 During these three stages, multiple cell types including macrophages, monocytes, lymphocytes, osteoclasts, and fibroblasts infiltrate the autograft from the host bone, while granulation tissue begins to form. Vascularization continues as a collagen matrix is formed and slowly mineralized. Remodeling of the healed defect, often in response to mechanical loading, occurs through both bone resorption and subsequent new bone formation.
While autografts are the clinical gold standard for bone grafting, the hazard of donor-site morbidity and a limited supply requires a feasible alternative. Allografts, tissue harvested from a donor or cadaver, are common alternatives to using autografts, but to reduce the likelihood of a host immune response or disease transmission, the donor tissue must be devitalized through a process that removes cellular and viral components. 5 This process removes the cells, blood, and proteins that are present with autografts, leaving the allograft as a largely structural implant with little to no inherent bioactivity and diminished local vascularity. Therefore, in allograft healing, graft incorporation relies only on cells, proteins, and tissues available from host bone and at the defect site. For trabecular allografts, this lack of bioactivity is less hindering to healing as the inherent pore structure of the tissue allows the host to infiltrate the allograft and heal but devitalization does impact more dense, cortical allografts. 6 Large-scale structural allografts (typically cortical bone taken from the diaphysis of long bones) have limited healing, where mineralized tissue usually forms along the cortex of the host bone and allograft. The lack of osteoclast-mediated allograft resorption or bone remodeling, leaves large segments of necrotic bone, weakening the defect site over time. The repetitive loading at these sites makes them vulnerable to destabilization and generation of small microfractures. 7, 8 As these allografts become less stable, non-unions (27-34%), JL receives royalties from Depuy, Inc. and serves on the board of the American Association of Hip and Knee surgeons. Grant sponsor: Musculoskeletal Transplant Foundation (MTF). Correspondence to: Yusuf Khan (T: þ1-860-679-4097; F: þ1-860-679-1553; E-mail: ykhan@uchc.edu) late graft fractures (24-27%), and infections (9-16%) occur which ultimately result in clinical failure. 9 In the hopes of improving large scale defect healing, we have developed a technique to "revitalize" allografts by incorporating molecules known to stimulate implant resorption and enhance new bone formation. The literature reports that delivering bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF) simultaneously yields better bone healing over either growth factor alone, and delivering them sequentially yields even better healing. [10] [11] [12] [13] The literature also suggests that VEGF may influence osteoclast precursor differentiation to mature osteoclasts [14] [15] [16] [17] which, when, delivered from devitalized allografts may increase the local osteoclast population to facilitate implant resorption, thereby paving the way for subsequent new bone formation. Given this, we have developed a method through which a thin, polymeric coating capable of retaining and delivering growth factors is applied to all surfaces of large-scale structural allografts, with the intention of delivering therapeutic molecules capable of enhancing bone-allograft healing. We have previously demonstrated the ability to deliver either VEGF or BMP-2 with two distinct delivery kinetics; short-and long-term. 18 Our studies demonstrated that BMP-2 released from the polymer-coated allograft resulted in robust bone formation in a rat segmental defect. However, the release of BMP-2 alone failed to show any significant bone resorption in vivo 18 substantiating the need to stimulate osteoclastogenesis.
We hypothesized that the sequential delivery of angiogenic/osteoclastogenic, and osteogenic growth factors from the coated allografts would improve osteoclastogenesis and bone formation, with the intention of improving healing outcomes of large-scale structural allograft implantations. In this report, we tested this premise and demonstrated the following: (i) the simultaneous delivery of BMP-2 and VEGF at once, each with distinct delivery kinetics; and (ii) the enhanced differentiation of osteoclast precursors into mature, bone-resorbing osteoclasts from the delivery of released VEGF.
MATERIALS AND METHODS

Allograft Harvest and Preparation
Allograft harvesting and preparation was based on previous work. 18 Briefly, tibial and femoral bone samples were harvested from male Sprague-Dawley rats (150-250 g). After cleaning of the soft tissue, the bone marrow was aspirated and bone segments were agitated in a chloroform solution overnight to reduce the residual fatty tissue. The long bones were cut into 5 mm longitudinal segments and autoclaved (121˚C and 15 PSI for 30 min) to remove biological and viral components.
Allograft Coating and Growth Factor Loading
To assess the potential for short-term and long-term release kinetics of distinct molecules from the same allograft, BMP-2 and VEGF were both loaded onto one coated allograft sample using one of two methods. Recombinant human BMP-2 (Genscript, Piscataway, NJ) was loaded into polymer-coated allografts through encapsulation within the polymer coating and VEGF (Mouse, Recombinant Expressed in Escherichia coli Product No. V4512, Sigma-Aldrich, St. Louis, MO) was loaded onto the same allograft sample through surface adsorption onto the polymer coating. For factor encapsulation, 50:50 PLGA (Lakeshore Biomaterials, Inc. Birmingham, AL) was dissolved in 1:8 (w/v) concentration of tetrahydrofuran (Fisher Scientific, Pittsburgh, PA). BMP-2 was then added to the polymer solution (500 mg/ml) prior to allograft coating. Each allograft was then placed in the barrel of a 3 cc syringe and the polymer solution was drawn into the syringe by pulling the plunger to fully coat the allograft across its endosteal and periosteal surfaces. This process was repeated by moving the plunger up and down to effectively rinse the allograft with the polymer. The allografts were then placed in a rotator at 4˚C overnight to achieve an even, continuous coating, followed by lyophilization to remove residual solvent. After lyophilization VEGF was adsorbed to the surface of the same coated allografts by placing them into a concentrated VEGF solution (5 mg/ml) for a period of 15 min to allow the protein to adsorb to the coating. Coated allografts were subsequently frozen at À20˚C for 20 h, lyophilized for an additional 24 h, and stored at À20˚C until use.
Growth Factor Release Kinetics Studies
Release kinetics of the growth factors were determined by placing the double-factor-loaded allografts (each loaded with both VEGF and BMP-2) in phosphate buffered saline (PBS) at 37˚C under constant agitation for 42 days, during which 800 ml samples of buffer were taken at specific intervals (2, 4, 6, 8, 12 , and 24 h, and 2, 3, 5, 7, 10, 14, 21, 28, and 42 days). Protein release was analyzed using the Quantikine Immunoassay kit (R&D systems, Minneapolis, MN) specific for each growth factor. The optical density of the aliquots of released protein was determined using a micro plate reader (Synergy TM HT, BioTek Inc, Winooski, VT) and correlated to protein concentration. Controls consisted of allograft coated with polymer but not loaded with either growth factor.
Differentiation of RAW264.7 Cells into Mature Osteoclasts
To assess the ability of VEGF to differentiate osteoclast precursors into osteoclasts, VEGF was added to RAW264.7 cell (an osteoclast precursor cell line) cultures manually to each well. This was done to isolate any effect the presence of the allograft and/or its polymeric coating may have on the osteoclast precursors. RAW264.7 cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD) and cultured in 25 cm 2 tissue culture flasks in ATCCformulated RPMI-1640 culture medium with 10% FBS, 1% penicillin/streptomycin at 37˚C in a humidified atmosphere containing 5% CO 2 . After 24-48 h of culture, RAW264.7 cells were detached using a cell scraper and seeded into 24-well plates at a density of 2.6 Â 10 4 cells/cm 2 in a-MEM culture media with 10% FBS, 1% penicillin/streptomycin. Four groups were evaluated in this study: (i) negative control: Cells cultured in a-MEM; no additives; (ii) positive control: Cells cultured in a-MEM with receptor activator of nuclear factor kappa-B ligand (RANKL 50 ng/ml) which is available endogenously 17 and is added to culture to replicate the in vivo environment; (iii) cells cultured in a-MEM treated with RANKL (50 ng/ml) and 10 ng/ml VEGF added directly to the culture; and (4) cells cultured in a-MEM treated with RANKL (50 ng/ml) and 100 ng/ml VEGF added directly to the DUAL FACTOR DELIVERY FOR ALLOGRAFT REMODELING culture. Cells from each group were cultured for 7 days and then fixed in 3.7% formalin. Cells were then stained with tartrate-resistant acid phosphatase (TRAP) using a commercial kit (Sigma). Cells that both stained positive for TRAP and contained three or more nuclei were considered osteoclasts, and were visualized with a Zeiss observer Z.1 light microscope (Carl Zeiss) and analyzed using NIH ImageJ software.
Isolation, Culture, and Differentiation of Bone Marrow Derived Mononuclear (BMM) Cells Primary bone marrow derived mononuclear cells (BMMs) were exposed to VEGF that was either added to cell culture wells as described above (to assess the functionality of osteoclast-precursors differentiated with VEGF independent of the allograft or polymer coating) and eluted directly from coated/loaded allografts (to confirm the bioactivity of the VEGF after it is released from the coated allograft) (see Fig. 1 ). BMMs were isolated from long bones of wild type mice aged 4-to 9-week-old, according to published protocols. 19 Briefly, long bones were excised from the mice, cleaned of soft tissue, and stored in PBS. The bone marrow of each bone was flushed out with a-MEM media that was supplemented with 10% FBS and 1% penicillin/streptomycin. Flushed marrow was centrifuged for 5 min at 1200 rpm. Cells were then resuspended in ACK buffer to lyse red blood cells and the suspension was then centrifuged for 5 min at 1200 rpm. Finally, cells were resuspended in complete media. Cells were then seeded on a petri dish (1 Â 10 8 cells/ 10 cm dish). Macrophage colony-stimulating factor (M-CSF) (30 ng/ml) was added and cells were cultured for 48 h in 5% CO 2 . Cells were then detached and seeded onto 24-well plates at a concentration of 50,000 cells/well. To support osteoclast differentiation, all cells were cultured in complete a-MEM media supplemented with 10% FBS, 1% penicillin/ streptomycin and M-CSF (30 ng/ml) to assess the following five experimental groups: (i) negative control: Cells cultured in media (no additional additives); (ii) positive control: Cells cultured in media with RANKL added (50 ng/ml); (iii) cells cultured in media with 100 ng/ml VEGF added (no RANKL); (iv) cells cultured in media with RANKL (50 ng/ml) and VEGF (100 ng/ml) added; and (v) cells cultured in media with RANKL (50 ng/ml) and $120 ng/ml VEGF eluted directly from coated/loaded allograft using a transwell with pore size 0.4 mm insert setup (see Fig. 1 ). Each group was cultured for 7 days and numbers of TRAP stained osteoclasts were counted as described above.
TRAP Staining TRAP (þ) cells were identified as osteoclasts for both RAW264.7 cell studies (on day 7 of culture) and BMM cell studies (on day 5 of culture) through histochemical staining using a commercially available kit (Sigma-Aldrich) as per manufacturer's instruction.
Osteoclast Functionality Assay
Osteoclasts differentiated from BMM cell isolations were assessed for in vitro functionality using two different methods: Quantification of resorbed hydroxyapatite coating, and identification of resorption pits from bone slices.
Hydroxyapatite Resorption Assay: BMM cells were plated in hydroxyapatite-coated Corning Osteo-Assay Surface 24-well plates (Corning Life Sciences) using the same culture media and cell density used in cell culture (see above). After 14 days of culture hydroxyapatite coated plates were washed with 1.2% sodium hypochlorite solution for 5 min to remove cells, rinsed with distilled water, and air-dried. For staining, plates were treated in dark at ambient temperature with 5% (w/v) silver nitrate solution for 30 min. Wells were then aspirated and washed for 5 min in distilled water. Wells were aspirated again, and 5% (w/v) sodium carbonate in 10% formalin was added. After a 5-min incubation at ambient temperature, plates were aspirated and air-dried at 37˚C prior to imaging. The resorption pits were imaged using a light microscope Zeiss observer Z.1 microscope (Carl Zeiss, Oberkochen, Germany) and percent resorption area was calculated using NIH ImageJ software.
Dentin Resorption Assay:
Bovine bone slices were used to assess resorption pits formed by mature osteoclasts. Briefly, the diaphyses of bovine femurs were cut transversely into 2-3 cm cylinders with a hacksaw. The cylinder was then cut into three segments and the marrow lifted out. Any adherent muscle, marrow, or periosteum was cleaned with a scalpel. The segments were then sonicated in warm water. The bone was given a final cleaning of any adherent tissue with a scalpel. Transverse slices 200 mm thick were made on the Isomet Low Speed Saw (Buehler, Lake Bluff, IL) with a wafering blade. The bone was then clamped tightly and slices cut at 200 mm intervals using 10% ethanol in Milli-Q water. These 200 mm slices were trimmed to produce the final 4.4 Â 4.4 Â 0.2 mm 3 bone slices. The bone slices were stored in 70% ethanol until use, then sterilized overnight with UV light in a sterile hood. On the day of experiment, bone slices were placed in 24 well plates (1 bone slice/well). BMMs (100,000 cells/bone slice) were plated and cultured according to the five different groups described above for 14 days. Culture medium was changed every 2-3 days. Bone slices were then fixed with 2.5% glutaraldehyde in PBS for 30 min at RT. Cells were then TRAP stained (Sigma kit #387A-1KT) and examined microscopically to observe TRAP-positive osteoclasts. Bone slices were sonicated for 5-15 min in distilled water to dislodge attached cells and then stained for 30-60 s with 1% Toluidine blue in 1% Borax buffer, rinsed in distilled water, air dried, and examined for the presence of resorption pits using light microscopy. The dentin slices were also imaged using scanning electron microscopy. Allografts were sputtercoated with gold/palladium for 60 s using a JEOL JSM-5900LV scanning electron microscope (JEOL USA, Peabody, MA) operated at 10.0 kV and imaged for evidence of resorption pits.
Statistical Analysis
A student's t-test (to compare two groups) or one-way analysis of variance with Tukey post-hoc testing, (for multiple group comparisons) was used to determine statistical significance with p < 0.05. Sample size for all protein release in vitro analysis was n ¼ 6. Sample size for cell studies was n ¼ 3.
RESULTS
In Vitro Growth Factor Release Kinetics
In vitro factor release studies showed the rate at which the growth factors were released from the coated allografts when VEGF was surface adsorbed onto the polymer coating and BMP-2 was encapsulated within the coating of the coated/loaded allograft. The simultaneous release of the two growth factors exhibited a largely sequential release pattern where VEGF release was predominantly at the earliest time points with 96.8% of the VEGF payload eluted between days 1 and 14 ( Fig. 2 gray line) , while the BMP-2 release followed a more sustained profile with less of an initial burst release over the entire study (Fig. 2  dark line) . In total, 135 ng of VEGF was released from the surface of the allograft coating, with no further release after day 10 ( Fig. 3) , while 300 ng of BMP-2 was released from within the polymer coating over the 42-day release study. Overall, this result demonstrated the ability to elicit short-term and long-term delivery kinetics with one growth factor mostly released prior to another from the same construct by using surface adsorption and encapsulation, respectively.
VEGF Stimulation of Osteoclast Activity
To assess the efficacy of VEGF as a stimulator of osteoclastogenesis, and to see whether this effect was dose-dependent, RAW 264.7 cells were cultured in the presence of both RANKL and a low or high concentration of VEGF. While mononuclear cells can exhibit TRAP-positive staining, in this study a cell had to stain positive for TRAP and also be multinucleated (three or more nuclei) to be considered osteoclast-like. There was a statistically significant increase in the number of multinucleated TRAP-positive cells when comparing cultures with RANKL alone and RANKL þ 10 ng/ml VEGF (Fig. 4) , indicating that combining VEGF and RANKL further stimulates osteoclastogenesis over RANKL alone. This effect was seen to be dosedependent as cultures containing RANKL þ 100 ng/ml VEGF showed an increase in TRAP-positive cells over RANKL þ 10 ng/ml VEGF cultures (Fig. 4) . Figure 2 . Growth factor release profiles from polymer-coated allografts containing both VEGF (surface adsorbed) and BMP-2 (encapsulated), simultaneously. Release profiles indicate a rapid burst release of VEGF from the surface of the coated allograft and a more sustained, longer-term release profile of BMP-2 from the polymer coating. This demonstrates the feasibility of delivering two growth factors from one coated allograft with temporal control.
DUAL FACTOR DELIVERY FOR ALLOGRAFT REMODELING
To evaluate the functionality of VEGF-differentiated osteoclasts, BMMs were cultured with VEGF similarly to RAW264.7 cells, and then assessed with TRAP staining and for bone resorption capability. To confirm the bioactivity of eluted VEGF from the allograft, BMMs were also placed below transwell inserts to allow culture in the VEGF released from the allograft, as depicted in Figure 1 . TRAP assay results confirmed the efficacy of released VEGF to induce osteoclast formation of BMMs (Fig. 5) and showed similar results to that of RAW264.7 cell lines. Groups treated with VEGF had significantly higher TRAPpositive multinucleated osteoclasts than those treated without VEGF. Further, data demonstrated no significant difference in the number of TRAP-positive multinucleated cells between the cultures, where VEGF was added directly (100 ng/ml), and where it was released from the coating, confirming that the process of coating and releasing VEGF from coated allografts did not alter its bioactivity.
Bone Resorption Assay
The ability of the osteoclasts differentiated from BMM cells to resorb bone was confirmed by staining osteoassay plates with Von Kossa stain. Figure 6 shows photomicrographs of synthetic hydroxyapatite mineral surfaces as black, while white regions reveal areas where resorption has occurred due to active acid secretion by differentiated osteoclasts. Our results showed that the group with VEGF released from the allografts revealed a significantly (p < 0.05) higher percent of resorption area over both positive and negative control groups (RANKL alone and no RANKL, respectively). These data suggest that the released VEGF from PLGA coated allograft enhances the differentiation of bone marrow derived monocytes into functional osteoclasts in vitro.
We also tested functionality of BMMs that were differentiated to osteoclasts via released VEGF on devitalized (and therefore cell-free) bovine bone chips to assess true bone resorption (Fig. 7) . SEM images revealed formation of resorption pits on bovine bone surface (Fig. 7D) as evidenced by comparison to untouched bone slices ( Fig. 7A and B) . The bone slices were also stained with TRAP, to confirm the presence of osteoclasts, and toluidine blue to visualize resorption pits. Multinucleated TRAP positive cells were observed on the surface of the bone slices and the resorption pits developed a blue to purple color. These results strongly support the notion that incorporating VEGF into coated and loaded allografts will not only help stimulate angiogenesis and early vascularization, 20 but also may likely facilitate allograft resorption via osteoclast precursor differentiation, which may encourage bone remodeling of the allograft.
DISCUSSION
Autografts are still considered the gold standard for bone grafting because of their biocompatibility and propensity to form bone, but limited supply and donorsite morbidities restrict their utility and mandate a viable alternative. 21 Allografts are either used alone or in combination with autografts and bone graft substitutes and, depending on the specifics of the defect site and the nature of the allograft, have a wide range of success. Since allografts are commonly harvested from cadavers, they are traditionally processed before use to remove or minimize any biological activity, thereby lessening any host immune response but also any inherent graft bioactivity. So, the degree to which the host tissue heals depends more on non-biological properties of the allograft like defect-size and graft architecture than inherent biological capabilities it may have possessed prior to processing. It is clear, however, that devitalizing allografts to render them safer for transplant hinders their functionality and results in inferior healing. 9, 22 One solution to this has been to add back this functionality or revitalize the allografts. Different approaches to revitalizing devitalized allografts have included, (i) creating a synthetic periosteum of cells 23, 24 ; (ii) binding and releasing genetic vectors to induce host cells to overexpress important growth factors for bone repair and remodeling 25, 26 ; (iii) modifying the physical structure of the allograft to encourage better host cell migration 27, 28 ; and (iv) adding a bioactive ceramic coating to the allograft itself. 29, 30 Each attempt has been moderately successful but also somewhat complex and challenging when considering scale-up and the requirements of large-scale manufacturing.
To address these concerns, we have developed a novel procedure where a very thin coating of degradable polymer has been added to the surface of long bone allografts and loaded with relevant growth factors such that they elute with a temporal precision shown to benefit bone repair. 18 By modifying an implant that is clinically viable and currently used in regular practice, and using materials and molecules that have long track records of safety and efficacy, we believe our approach may be accepted in the clinic, and by applying this to a known clinical challenge by directly addressing the issues at the heart of the challenge, we believe this approach has the potential to be an important tool to the orthopedic surgeon. This coated loaded allograft has been shown here to deliver both VEGF and BMP-2 from the surfaces of the long bone allograft such that the VEGF releases in a burst over the first few days after implantation and is followed by BMP-2 release over an extended period of time, up to 4 weeks longer. In our previous work, we established a methodology to apply a polymer coating onto the surface of the allograft thin enough to maintain its inherent pore structure (which facilitates revascularization and bone formation) and still act as a vehicle to deliver growth factors, VEGF, and BMP-2, to the defect site. We examined both the release kinetics of each growth factor independently from polymer-coated allografts and the osteogenicity of the allograft through the bioactivity of the released BMP-2 in vitro and in vivo. 18 We showed how VEGF and BMP-2, when loaded individually, can be released with two distinct delivery kinetics depending on how they are loaded onto the allograft. The present study was intended to build upon that work to combine the two independent findings from the first paper and focus on the "simultaneous and sequential" delivery of VEGF and BMP-2 from the same coated allograft and There was a significant increase in osteoclast differentiation between the groups with and without VEGF, which confirms the bioactivity of the protein. There is no effect of VEGF alone on osteoclastic differentiation. Significance between groups is designated with ( Ã ) ¼ p < 0.05. Data are mean AE SD, n ¼ 3 independent experiments. Scale bar represents 100 mm.
DUAL FACTOR DELIVERY FOR ALLOGRAFT REMODELING the osteoclastogenicity of the released VEGF, when combined with endogenously available RANKL in concentrations shown in the literature to be appropriate for in vitro osteoclast differentiation, [31] [32] [33] [34] to improve the overall healing potential of allografts for large scale bone defect repair. Our results show that surface adsorbed VEGF is released rapidly from the double loaded allograft, with over 96% coming off in the first 4 days. While BMP-2 release also begins in the short-term, its release is more gradual and extends over a longer period of time than the VEGF, with more than 50% of its payload still bound to the allograft after VEGF is almost completely eluted. This demonstrates that we can deliver both VEGF and BMP-2 from the same construct, and preferentially have the vast majority of the VEGF elute first, a temporal specificity that has been shown in the literature to be important for bone repair and regeneration. [10] [11] [12] [13] While the two growth factors do elute simultaneously at the earliest time points, VEGF elutes at 3-5x that of BMP-2. At later time points, BMP-2 continues to elute after the entire VEGF payload has been released. So, while not perfectly sequential, the release is dominated in the earliest time points by VEGF and at the later time points by BMP-2.
BMP-2 and VEGF, two of the most commonly studied growth factors in bone repair, are critically important on their own but also have interconnected roles in the healing process. Peng et al., for instance, have shown that VEGF antagonists actually reduce the induction capacity BMP-2 to form bone, while BMP-2 in the presence of VEGF showed enhanced bone formation. 10 Further, the degree of bone formation after exposure to both factors was partially dependent on the ratio of one to the other, with higher amounts of BMP-2 compared to VEGF eliciting more bone formation than the reverse. Kempen et al. engineered a composite scaffold consisting of PLGA microspheres loaded with BMP-2, embedded in a poly (propylene) scaffold, surrounded by a VEGF-loaded gelatin hydrogel. Despite the release of 98% of the VEGF within the first 14 days, the VEGF þ BMP-2 group formed more vessels and bone than the other groups. 11 Patel et al. reported that the sequential delivery of VEGF and BMP-2 accelerates the healing process through a rat cranial critical-size defect model that evaluated the angiogenic and osteogenic response to porous poly (propylene fumarate) scaffolds with gelatin microparticles that released VEGF and BMP-2. The experimental constructs that released both BMP-2 and VEGF showed accelerated bone healing over those releasing BMP-2 or VEGF alone. 12 In another study of co-release of VEGF and BMP-2 examining the chemotactic role of each molecule, Ramazanoglu et al. examined expressions of collagen type I, Osteocalcin, and Osteopontin. Increased collagen I from VEGF þ BMP-2 groups confirmed the chemotactic migration behavior elicited by VEGF on osteoblasts. At week 4, the VEGF þ BMP-2 group showed higher osteopontin expression. Since osteopontin regulates bone remodeling by helping osteoclasts bind to bone, an increase in its expression was interpreted as an indication of bone remodeling. 13 Thus, the physiological basis for delivering both VEGF and BMP-2 from the same allograft is well founded, given their traditional roles as vasculogenic and osteogenic molecules, respectively. [10] [11] [12] [13] 20, 35, 36 However, less well known are the roles of VEGF in regulating both bone formation and resorption through their respective cell types.
VEGF plays a significant role in osteoblast functionality. Studies have shown that VEGF has a dosedependent chemoattractive effect on primary human osteoblasts and human mesenchymal progenitor cells 37, 38 and is responsible for regulating blood vessel invasion (neovascularization) into hypertrophic cartilage. VEGF also plays a vital role in osteoclast differentiation and bone resorption.
14-17 Nakagawa et al. found that VEGF caused a dose-and time-dependent increase in the area of bone resorption pits excavated by the purified rabbit mature osteoclast via two distinct VEGF receptors, KDR/Flk-1 and Flt-1, in osteoclasts at the gene and protein levels, and VEGF induced tyrosine phosphorylation of proteins in osteoclasts. Thus, osteoclastic function and angiogenesis are upregulated by a common mediator, VEGF.
14 Helmrich et al. showed that VEGF in a defect site not only improved vascularization, but also increased the recruitment of the TRAP and Cathepsin K-positive osteoclasts. 15 Kaku et al. showed in osteopetrotic op/op mice with a severe osteoclast deficiency that injection of VEGF induced osteoclast formation during experimental tooth movement. 16 In the present study, we have substantiated the osteoclastogenic capacity of VEGF and verified that when released from the coated allograft its capacity is retained. VEGF released from coated allografts resulted in enhanced differentiation of osteoclast progenitors in a dose dependent manner, and bone resorption studies verified that the differentiated osteoclasts were fully functional as bone resorbing cells. While in our studies, we were careful to isolate VEGF release when assessing osteoclastic precursor response, we do acknowledge that future studies should be done to fully understand how the partial overlap of VEGF and BMP-2 delivery that we see may impact this response given the design of our delivery system. Given that allografts, particularly large scale cortical allografts, have a failure rate of 30-60% at the 10-year mark 9 in part due to lack of vascularization and limited remodeling via creeping substitution, 22 it is the belief that the early release of VEGF from the coated allografts will both encourage neovascularization at the defect site and also differentiate osteoclast precursors to fully functional osteoclasts so the implanted allograft becomes a temporary strut that is resorbed to make way for new bone rather than DUAL FACTOR DELIVERY FOR ALLOGRAFT REMODELING a semi-permanent necrotic tissue that is destined to fail years down the line.
CONCLUSIONS
In this study, we have demonstrated the dual release of VEGF and BMP-2 with temporal precision from one polymer-coated cortical allograft. Burst release of VEGF was confined to the first week, while BMP-2 release was extended over several weeks of elution. Released VEGF, traditionally tasked with neovascularization, was shown to effect osteoclast progenitor cells and induce them to mature, functional osteoclasts capable of resorbing bone. This simple but effective method of delivering with temporal precision, two important molecules for bone repair may serve to provide the orthopedic surgeon with a new tool in the armamentarium for treating large scale bone injuries brought about by tumor resection and trauma, and may serve to reduce or eliminate the long-term complications seen with the traditional use of devitalized structural allografts.
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